Double-Barreled antibody attack aims to wipe out hidden myeloma cells
Disease control
Recruiting now
This Phase 2 trial tests whether two bispecific antibody drugs, talquetamab and teclistamab, can eliminate remaining cancer cells in newly diagnosed multiple myeloma patients who still have detectable disease after initial treatment. About 50 participants will receive talquetamab…
Phase: PHASE2 • Sponsor: Noffar Bar • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC